An increasing number of studies have confirmed that inhibition of HGF/c-MET signaling is an effective therapeutic strategy for suppression of multiple human cancers, such as non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), gastric cancer, colorectal cancer, ovarian cancer, bladder cancer, head and neck cancer and cervical cancer [2, 8–14]. This evidence concerns the gene MET and non-small cell lung carcinoma.